Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 4(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04635241Phase 2Completed

Inhaled Heparin for Hospitalised COVID-19 Patients

Role: collaborator

NCT04397510Phase 4Terminated

Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury

Role: lead

NCT04723563Phase 4Completed

Nebulized Heparin for the Treatment of COVID-19

Role: lead

All 3 trials loaded